PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 1 | 1 |
Article title

Molecular Inhibitors in Targeted Therapy

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Keywords
Publisher

Year
Volume
1
Issue
1
Physical description
Dates
online
4 - 5 - 2015
Contributors
author
  • IBB-Institute for
    Biotechnology and Bioengineering, Centre for Molecular
    and Structural Biomedicine (CBME), University of Algarve,
    Campus de Gambelas, 8005-139 Faro, Portugal; Regenerative
    Medicine Program, Department of Biomedical Sciences and
    Medicine,University of Algarve, Campus de Gambelas, 8005-139
    Faro, Portugal, walink@ualg.pt
References
  • [1] Drews J., Drug discovery: a historical perspective, Science,2000, 287, 1960-1964
  • [2] Vane J.R., Inhibition of prostaglandin synthesis as amechanism of action for aspirin-like drugs, Nat. New Biol. 1971,231, 232-235
  • [3. Kauselmann G., Dopazo A., Link W., Identification of diseaserelevantgenes for molecularly-targeted drug discovery, Currentcancer drug targets, 2012, 12, 1-13
  • [4] Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S.,Leszczyniecka M., et al., Validating cancer drug targets, Nature,2006, 441, 451-456
  • [5] Kola I., Landis J., Can the pharmaceutical industry reduceattrition rates? Nature reviews Drug discovery, 2004, 3, 711-715
  • [6] Link W., Madureira P.A., Hill R., Identifying new targetsfor personalized medicine, eLS, John Wiley & Sons, Ltd:Chichester, 2013, DOI: 10.1002/9780470015902.a0024865[Crossref]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_1515_motth-2015-0001
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.